Statement: acute myocardial infarction, cardiopulmonary failure, and supraventricular tachycardia are more prevalent in the first cohort of the secondary clinical trial than in the entire patient population of the primary clinical trial.
Primary_evidence: Adverse Events 1:   Total: 0/0 Adverse Events 2:
Secondary_evidence: Adverse Events 1:   Total: 59/199 (29.65%)   Anaemia 7/199 (3.52%)   Thrombocytopenia 2/199 (1.01%)   Acute myocardial infarction 0/199 (0.00%)   Atrial fibrillation 1/199 (0.50%)   Cardiac arrest 1/199 (0.50%)   Cardiac failure 1/199 (0.50%)   Cardiopulmonary failure 1/199 (0.50%)   Left ventricular failure 1/199 (0.50%)   Supraventricular tachycardia 0/199 (0.00%)   Ventricular tachycardia 1/199 (0.50%) Adverse Events 2:   Total: 16/36 (44.44%)   Anaemia 2/36 (5.56%)   Thrombocytopenia 1/36 (2.78%)   Acute myocardial infarction 1/36 (2.78%)   Atrial fibrillation 0/36 (0.00%)   Cardiac arrest 0/36 (0.00%)   Cardiac failure 0/36 (0.00%)   Cardiopulmonary failure 0/36 (0.00%)   Left ventricular failure 0/36 (0.00%)   Supraventricular tachycardia 1/36 (2.78%)   Ventricular tachycardia 0/36 (0.00%)